Nitrite and myocardial ischaemia reperfusion injury. Where are we now?
Nitrite and myocardial ischaemia reperfusion injury. Where are we now?
Cardiovascular disease remains the leading cause of death worldwide despite major advances in technology and treatment, with coronary heart disease (CHD) being a key contributor. Following an acute myocardial infarction (AMI), it is imperative that blood flow is rapidly restored to the ischaemic myocardium. However, this restoration is associated with an increased risk of additional complications and further cardiomyocyte death, termed myocardial ischaemia reperfusion injury (IRI). Endogenously produced nitric oxide (NO) plays an important role in protecting the myocardium from IRI. It is well established that NO mediates many of its downstream functions through the 'canonical' NO-sGC-cGMP pathway, which is vital for cardiovascular homeostasis; however, this pathway can become impaired in the face of inadequate delivery of necessary substrates, in particular L-arginine, oxygen and reducing equivalents. Recently, it has been shown that during conditions of ischaemia an alternative pathway for NO generation exists, which has become known as the 'nitrate-nitrite-NO pathway'. This pathway has been reported to improve endothelial dysfunction, protect against myocardial IRI and attenuate infarct size in various experimental models. Furthermore, emerging evidence suggests that nitrite itself provides multi-faceted protection, in an NO-independent fashion, against a myriad of pathophysiologies attributed to IRI. In this review, we explore the existing pre-clinical and clinical evidence for the role of nitrate and nitrite in cardioprotection and discuss the lessons learnt from the clinical trials for nitrite as a perconditioning agent. We also discuss the potential future for nitrite as a pre-conditioning intervention in man.
Cardiotonic Agents/pharmacology, Clinical Trials as Topic, Humans, Myocardial Reperfusion Injury/prevention & control, Nitrites/pharmacology
107819
Griffiths, Kayleigh
0a807d8e-54aa-4c82-b5e7-3656cde837fd
Lee, Jordan J.
3f24f9f8-1acb-4cf7-aa10-783dfeaecab4
Frenneaux, Michael P.
82824b6d-51f1-4b31-9f7a-5b4746d59833
Feelisch, Martin
8c1b9965-8614-4e85-b2c6-458a2e17eafd
Madhani, Melanie
63a48cca-67b7-41ae-bc79-0f4a166f0750
July 2021
Griffiths, Kayleigh
0a807d8e-54aa-4c82-b5e7-3656cde837fd
Lee, Jordan J.
3f24f9f8-1acb-4cf7-aa10-783dfeaecab4
Frenneaux, Michael P.
82824b6d-51f1-4b31-9f7a-5b4746d59833
Feelisch, Martin
8c1b9965-8614-4e85-b2c6-458a2e17eafd
Madhani, Melanie
63a48cca-67b7-41ae-bc79-0f4a166f0750
Griffiths, Kayleigh, Lee, Jordan J., Frenneaux, Michael P., Feelisch, Martin and Madhani, Melanie
(2021)
Nitrite and myocardial ischaemia reperfusion injury. Where are we now?
Pharmacology & Therapeutics, 223, .
(doi:10.1016/j.pharmthera.2021.107819).
Abstract
Cardiovascular disease remains the leading cause of death worldwide despite major advances in technology and treatment, with coronary heart disease (CHD) being a key contributor. Following an acute myocardial infarction (AMI), it is imperative that blood flow is rapidly restored to the ischaemic myocardium. However, this restoration is associated with an increased risk of additional complications and further cardiomyocyte death, termed myocardial ischaemia reperfusion injury (IRI). Endogenously produced nitric oxide (NO) plays an important role in protecting the myocardium from IRI. It is well established that NO mediates many of its downstream functions through the 'canonical' NO-sGC-cGMP pathway, which is vital for cardiovascular homeostasis; however, this pathway can become impaired in the face of inadequate delivery of necessary substrates, in particular L-arginine, oxygen and reducing equivalents. Recently, it has been shown that during conditions of ischaemia an alternative pathway for NO generation exists, which has become known as the 'nitrate-nitrite-NO pathway'. This pathway has been reported to improve endothelial dysfunction, protect against myocardial IRI and attenuate infarct size in various experimental models. Furthermore, emerging evidence suggests that nitrite itself provides multi-faceted protection, in an NO-independent fashion, against a myriad of pathophysiologies attributed to IRI. In this review, we explore the existing pre-clinical and clinical evidence for the role of nitrate and nitrite in cardioprotection and discuss the lessons learnt from the clinical trials for nitrite as a perconditioning agent. We also discuss the potential future for nitrite as a pre-conditioning intervention in man.
This record has no associated files available for download.
More information
e-pub ahead of print date: 15 February 2021
Published date: July 2021
Keywords:
Cardiotonic Agents/pharmacology, Clinical Trials as Topic, Humans, Myocardial Reperfusion Injury/prevention & control, Nitrites/pharmacology
Identifiers
Local EPrints ID: 456297
URI: http://eprints.soton.ac.uk/id/eprint/456297
ISSN: 0163-7258
PURE UUID: e15878a5-0318-4d82-83f1-0cc2ef354fe3
Catalogue record
Date deposited: 27 Apr 2022 02:06
Last modified: 17 Mar 2024 03:27
Export record
Altmetrics
Contributors
Author:
Kayleigh Griffiths
Author:
Jordan J. Lee
Author:
Michael P. Frenneaux
Author:
Melanie Madhani
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics